ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in Budapest, Budapest

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Renal Cell Carcinoma
Squamous Cell Carcinoma
Lung Cancer

Melanoma trials near Budapest, Budapest, HUN:

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (COLUMBUS-AD)

the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant setting of BRAF V600E/K mutant stage IIB/C melanoma...

Active, not recruiting
Melanoma
Drug: Placebo to match Encorafenib ; Placebo to match Binimetinib
Drug: Encorafenib and Binimetinib

Phase 3

Pierre Fabre
Pierre Fabre

Budapest, Hungary and 154 other locations

binimetinib, and pembrolizumab) given together for the treatment of melanoma that:* is advanced or metastatic (spread to other parts of the ...

Active, not recruiting
Melanoma
Drug: Binimetinib
Drug: Encorafenib

Phase 3

Pfizer
Pfizer

Budapest, Hungary and 227 other locations

with previously untreated unresectable or metastatic (advanced) melanoma.Patients will be stratified on the basis of the following factors; ...

Active, not recruiting
Unresectable Melanoma
Metastatic Melanoma
Drug: IO102-IO103
Drug: Pembrolizumab

Phase 3

IO Biotech

Budapest, Hungary and 111 other locations

(Spartalizumab (PDR001)), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in unresectable or metastatic BRAF V600 mutant melanoma...

Active, not recruiting
Melanoma
Drug: Trametinib
Drug: Dabrafenib

Phase 3

Novartis
Novartis

Budapest, Hungary and 178 other locations

The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma....

Active, not recruiting
Melanoma
Drug: Nivolumab
Other: Placebo matching Nivolumab

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Budapest, Hungary and 135 other locations

in patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation. A total of approximately 900 patients will be...

Active, not recruiting
Melanoma
Drug: MEK162
Drug: vemurafenib

Phase 3

Pfizer
Pfizer

Budapest, Hungary and 378 other locations

+ cobimetinib + vemurafenib in patients with previously untreated BRAFv600 mutation-positive metastatic or unresectable locally advanced melanoma...

Active, not recruiting
Melanoma
Drug: Atezolizumab Placebo
Drug: Cobimetinib

Phase 3

Roche
Roche

Budapest, Hungary and 115 other locations

This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global De...

Enrolling
Melanoma
Solid Tumor
Drug: dabrafenib
Drug: trametinib

Phase 4

Novartis
Novartis

Budapest, Hungary and 26 other locations

cell, pancreatic and biliary duct, endometrial, melanoma and urothelial tumors. This study contains two parts, single agent dose escalation...

Active, not recruiting
Melanoma Cancer
Endometrial Cancer
Drug: PF-06940434
Drug: PF-06801591

Phase 1

Pfizer
Pfizer

Komárno, Slovakia and 40 other locations

A Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability of KY1044 as single agent and in combination with anti-...

Active, not recruiting
Melanoma
Esophageal Cancer
Drug: KY1044
Drug: KY1044 and atezolizumab

Phase 1, Phase 2

Kymab
Kymab

Budapest, Hungary and 21 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems